84 related articles for article (PubMed ID: 20873967)
21. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
23. (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells.
Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Kubota M; Adachi S; Tsurumi H; Hara Y; Moriwaki H
Chem Biol Interact; 2010 May; 185(3):247-52. PubMed ID: 20346928
[TBL] [Abstract][Full Text] [Related]
24. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
25. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.
Rivet J; Mourah S; Murata H; Mounier N; Pisonero H; Mongiat-Artus P; Teillac P; Calvo F; Janin A; Dosquet C
Cancer; 2008 Jan; 112(2):433-42. PubMed ID: 18041056
[TBL] [Abstract][Full Text] [Related]
26. [Study on the role of angiogenesis and related factors in leukemias].
Zhang Y; Gu J; Wang M; Ma L; Wang XL; He B; Sun M
Zhonghua Xue Ye Xue Za Zhi; 2005 Mar; 26(3):175-8. PubMed ID: 15946533
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients.
Ranieri G; Coviello M; Patruno R; Valerio P; Martino D; Milella P; Catalano V; Scotto F; De Ceglie A; Quaranta M; Ribatti D; Pellecchia A
Oncol Rep; 2004 Oct; 12(4):817-20. PubMed ID: 15375505
[TBL] [Abstract][Full Text] [Related]
28. Changes in circulating levels of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 after carotid endarterectomy.
Papalambros E; Georgopoulos S; Sigala F; Vourliotakis G; Chrisostomidis G; Venetsanou K; Hadjoulis G; Felekouras E; Bastounis E
Int J Mol Med; 2004 Jul; 14(1):133-6. PubMed ID: 15202028
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma.
Mylona E; Alexandrou P; Giannopoulou I; Liapis G; Sofia M; Keramopoulos A; Nakopoulou L
Gynecol Oncol; 2007 Mar; 104(3):557-63. PubMed ID: 17150246
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Mylona E; Alexandrou P; Mpakali A; Giannopoulou I; Liapis G; Markaki S; Keramopoulos A; Nakopoulou L
Eur J Surg Oncol; 2007 Apr; 33(3):294-300. PubMed ID: 17129704
[TBL] [Abstract][Full Text] [Related]
31. Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma.
Ono T; Miki C
Am J Gastroenterol; 2000 Apr; 95(4):1062-7. PubMed ID: 10763960
[TBL] [Abstract][Full Text] [Related]
32. Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: a pilot study.
Yilmaztepe A; Ulukaya E; Zik B; Yagci A; Sevimli A; Yilmaz M; Erdogan BB; Koc M; Akgoz S; Karadag M; Tokullugil A
Cancer Invest; 2007 Aug; 25(5):322-7. PubMed ID: 17661207
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
34. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
[TBL] [Abstract][Full Text] [Related]
35. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume.
Davies MM; Jonas SK; Kaur S; Allen-Mersh TG
Br J Cancer; 2000 Mar; 82(5):1004-8. PubMed ID: 10737380
[TBL] [Abstract][Full Text] [Related]
36. [Clinical value of preoperative serum VEGF, CRP and IL-6 levels in colorectal carcinoma].
Li ZP; Han JQ; Meng XW; Yang YF
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):795-9. PubMed ID: 21163075
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer?
Broll R; Erdmann H; Duchrow M; Oevermann E; Schwandner O; Markert U; Bruch HP; Windhövel U
Eur J Surg Oncol; 2001 Feb; 27(1):37-42. PubMed ID: 11237490
[TBL] [Abstract][Full Text] [Related]
38. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
[TBL] [Abstract][Full Text] [Related]
39. Plasma VEGF-A and its soluble receptor R1 correlate with the clinical stage of colorectal cancer.
Myśliwiec P; Piotrowski Z; Zalewski B; Kukliński A; Pawlak K
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():85-7. PubMed ID: 15638384
[TBL] [Abstract][Full Text] [Related]
40. Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells.
Kim SJ; Seo JH; Lee YJ; Yoon JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Oncology; 2005; 68(2-3):204-11. PubMed ID: 16015035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
